Oxbow Advisors LLC Sells 218 Shares of Eli Lilly and Company $LLY

Oxbow Advisors LLC lowered its position in shares of Eli Lilly and Company (NYSE:LLY) by 23.1% during the second quarter, HoldingsChannel.com reports. The fund owned 727 shares of the company’s stock after selling 218 shares during the quarter. Oxbow Advisors LLC’s holdings in Eli Lilly and Company were worth $566,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds also recently made changes to their positions in LLY. WestEnd Advisors LLC boosted its position in shares of Eli Lilly and Company by 210.0% during the 1st quarter. WestEnd Advisors LLC now owns 31 shares of the company’s stock worth $26,000 after purchasing an additional 21 shares in the last quarter. Wealth Preservation Advisors LLC bought a new position in shares of Eli Lilly and Company during the 1st quarter worth about $27,000. Citizens National Bank Trust Department boosted its position in shares of Eli Lilly and Company by 180.0% during the 1st quarter. Citizens National Bank Trust Department now owns 42 shares of the company’s stock worth $35,000 after purchasing an additional 27 shares in the last quarter. Financial Gravity Asset Management Inc. bought a new position in shares of Eli Lilly and Company during the 1st quarter worth about $40,000. Finally, TD Capital Management LLC boosted its position in shares of Eli Lilly and Company by 129.2% during the 1st quarter. TD Capital Management LLC now owns 55 shares of the company’s stock worth $46,000 after purchasing an additional 31 shares in the last quarter. Institutional investors own 82.53% of the company’s stock.

Eli Lilly and Company Trading Down 1.0%

NYSE:LLY opened at $818.45 on Friday. The company has a debt-to-equity ratio of 1.86, a quick ratio of 1.00 and a current ratio of 1.28. The firm has a market cap of $774.63 billion, a price-to-earnings ratio of 53.49, a price-to-earnings-growth ratio of 1.18 and a beta of 0.47. Eli Lilly and Company has a 52 week low of $623.78 and a 52 week high of $935.63. The firm has a 50-day moving average price of $749.52 and a two-hundred day moving average price of $766.23.

Eli Lilly and Company (NYSE:LLY) last posted its quarterly earnings data on Thursday, August 7th. The company reported $6.31 EPS for the quarter, beating the consensus estimate of $5.59 by $0.72. The firm had revenue of $15.56 billion during the quarter, compared to analyst estimates of $14.40 billion. Eli Lilly and Company had a net margin of 25.91% and a return on equity of 92.72%. The company’s revenue for the quarter was up 37.6% on a year-over-year basis. During the same quarter last year, the business posted $3.92 EPS. Eli Lilly and Company has set its FY 2025 guidance at 21.750-23.000 EPS. On average, equities analysts expect that Eli Lilly and Company will post 23.48 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

A number of equities analysts have recently issued reports on the stock. The Goldman Sachs Group increased their price objective on shares of Eli Lilly and Company from $876.00 to $879.00 and gave the stock a “buy” rating in a research report on Friday, October 10th. Weiss Ratings restated a “hold (c+)” rating on shares of Eli Lilly and Company in a report on Wednesday, October 8th. UBS Group lowered their target price on shares of Eli Lilly and Company from $1,050.00 to $895.00 and set a “buy” rating on the stock in a report on Friday, August 8th. Daiwa America lowered shares of Eli Lilly and Company from a “strong-buy” rating to a “hold” rating in a report on Sunday, August 17th. Finally, Wall Street Zen lowered shares of Eli Lilly and Company from a “strong-buy” rating to a “buy” rating in a report on Saturday, September 20th. One equities research analyst has rated the stock with a Strong Buy rating, fourteen have assigned a Buy rating and nine have assigned a Hold rating to the stock. According to MarketBeat, the stock has an average rating of “Moderate Buy” and an average price target of $939.12.

Insider Transactions at Eli Lilly and Company

In other news, Director Gabrielle Sulzberger acquired 117 shares of the firm’s stock in a transaction on Tuesday, August 12th. The stock was purchased at an average price of $641.18 per share, for a total transaction of $75,018.06. Following the purchase, the director owned 2,703 shares in the company, valued at approximately $1,733,109.54. This represents a 4.52% increase in their position. The purchase was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, Director Jamere Jackson acquired 200 shares of the firm’s stock in a transaction on Friday, August 8th. The stock was purchased at an average price of $639.56 per share, with a total value of $127,912.00. Following the purchase, the director owned 9,402 shares in the company, valued at approximately $6,013,143.12. The trade was a 2.17% increase in their position. The disclosure for this purchase can be found here. In the last 90 days, insiders have bought 4,514 shares of company stock worth $2,894,841. Company insiders own 0.13% of the company’s stock.

Eli Lilly and Company Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.